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348 Epidemiological and clinical features of patients attending a
reference cystic ﬁbrosis center in Argentina
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Several factors are related to the prognosis in CF patients such as age, gender,
genetics, nutritional status, bacterial colonization and pulmonary function. The aim
of the study was to report epidemiological and clinical features of our patients.
Material and Methods: Observational, cross-sectional study. Clinical reports from
patients attended at our Center during 2011 were reviewed. Age, gender, screening
diagnosis, genetics, pancreatic sufﬁciency, Z-score BMI, Z-score V′maxFRC, FEV1
and chronical bacterial colonization (more than 50% of at least 4 sputum cultures
during the year, of each bacteria) were the variables analyzed.
Results: We included 110 patients (56 males). Median current age was 6 years old
(3.4 to 11.5 interquartile range) with 0.33 years old as a median age at diagnosis
(0.16 to 1.16). 39% of patients were diagnosed by screening. 86% of patients had
p.F508del mutation (46% homozygous). 15% of patients had pancreatic sufﬁciency.
27% were chronically colonized with Pseudomonas aeruginosa (PA), 21% with
methicillin-resistant Staphylococcus aureus (MRSA) and 4.5% with Burkholderia
cepacia complex (Bcc). The median Z-score weight/age for patients less than 2 years
old was −0.13 (−1.2 to 0.4). The median Z-score BMI was −0.26 (−0.8 to 0.3).
36% of patients had an infant pulmonary function test before 1 year old; the median
Z-score V′maxFRC was −0.5 (−1.6 to 0.6). The median FEV1 was 84% of predictive
values (57 to 99).
Conclusions: A high percentage of our patients were diagnosed by screening and
have p.F508del mutation. Chronic colonization with MRSA and PA is frequent.
Patients have an acceptable pulmonary function and nutritional status.
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Aim: To evaluate CFTR mutations spectrum and clinical proﬁle in patients with
cystic ﬁbrosis (CF) from Republic of Moldova.
Materials and Methods: This study included 61 patients (29 boys) with CF, age
range 5 months to 24 years (mean age 9.08±1.02 years). Genetic examination
was performed for 36 CFTR mutations in Germany and for 35 mutations with
subsequent splicing in France. The sweat test was realized on Macroduct (USA)
and Esudose (France) systems.
Results: Genetic examination allowed the identiﬁcation of homozygous state by
F508del mutation in 52.08% children, 4.16% cases homozygous by other muta-
tions, 27.08% heterozygous by F508del and 16.66% heterozygous composite. The
genotype remained unknown in 8.19% children. The mean age of CF diagnostic
is 2.45±0.55 years. The diagnostic of CF was established at the age of <1 year
in 60.65% children, 1−5 year in 26.22% children, 5−10 years in 3.27% cases,
>10 years in 9.83% cases. The age distribution was 7.54% cases of infants, 56.60%
children aged 1−10 years and 16.98% children aged 10−18 years and 18.86%
adults older than 18 years. In the period of 2005–2011, 8 children died (mean age
5.34±2.48 years). Pseudomonas aeruginosa was isolated in 57.37% cases. HRCT
has revealed bronchiectasis in 60.65% cases. The spirography showed impairments
of pulmonary function (FVC − 60.75±2.76%, FEV1 − 59.46±3.50%). The BMI
was below 25 percentile in 53.8% patients.
Conclusion: There F508del mutation was identiﬁed in 79.16% children with CF
from Republic of Moldova. The mean age of diagnostic is delayed, but in most
cases it is established in the ﬁrst year of life. Bronchopulmonary impaired and
malnutrition are frequently identiﬁed.
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With improvements in the early diagnosis and treatment of cystic ﬁbrosis (CF) over
the past 50 years, there has been a dramatic increase in survival. It is important to
understand whether these patients are at risk of other complications now they are
surviving longer into adulthood. Some reports have suggested there is an increase
risk of bowel and other cancers in CF patients but there is little data about these
occurring in Australian and New Zealand CF patients.
Objective: The aim of the study was to establish baseline data about the occurrence
and types of cancer in adult CF patients in Australasia.
Method: A questionnaire was sent out in December 2010 to Australasian adult
CF centres. The deidentiﬁed data collected included: phenotypic features of CF,
genotype of CF, presentation with cancer, histology and site of cancer, family history
of cancer, transplant and immunosuppression history and treatment and outcome of
cancer.
Results: Three centres reported no malignancies. A total of 23 patients with cancer,
12 female and 11 male, have been reported to date and 2 patients had 2 cancers.
Fourteen (14) gastro-intestinal tract cancers were identiﬁed; most were large bowel
cancers. For 3 patients, there was a signiﬁcant family history. A number of other
malignancies were reported including skin cancers, breast cancer and renal cancer.
Seven (7) patients had received bilateral lung transplants and some of these had
post-transplant lymphoproliferative disorder.
Given the cancers identiﬁed in the baseline data, subsequent studies are planned to
consider the need for patient screening and possible aetiological factors.
